A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone o
A phase 2 trial of Telisotuzumab adizutecan in colorectal cancer, run by AbbVie, now recruiting.
Overview
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease is a phase 2 interventional study registered as NCT07023289 by AbbVie, with 140 participants planned, started 2025-09-02 and due to reach its primary completion in 2029-11. Interventions recorded: Telisotuzumab Adizutecan, Standard of Care. Conditions listed: Colorectal Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialA Study to Access Intravenous (IV) Telisotuzumab Adizutecan in Combination With IV Bevacizumab Compared to Standard of Care IV Bevacizumabin Combination With Oral Trifluridine and Tipiracil in Adult Participants With Refractory Metastatic Colorectal Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialA Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).
- TrialA Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).
- TrialA Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).
- TrialStudy to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unrese
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialA Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil,
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan), Colorectal cancer.
- TrialStudy to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations
Shares Telisotuzumab adizutecan, AbbVie (incl. ImmunoGen, Capstan).